DOP061 Phase III randomised, double-blind, controlled trial to compare biosimilar infliximab (CT-P13) with innovator infliximab in patients with active Crohn's disease: early efficacy and safety results
2017
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
15
Citations
NaN
KQI